MagnetisMM-3 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

35,990 results for “MagnetisMM-3”

NHS Scotland Approves Elranatamab and Teclistamab for Relapsed/Refractory Multiple Myeloma

Elranatamab Plus Iberdomide Combination Achieves 95.5% Response Rate in Relapsed/Refractory Multiple Myeloma

GPRC5D Emerges as Promising Target in Multiple Myeloma Clinical Trials

Pfizer Launches Phase 3 Trial Testing Elranatamab Triple Combination for Newly Diagnosed Multiple Myeloma

Elranatamab Achieves 61% Response Rate in Heavily Pretreated Multiple Myeloma Patients

Novel BCMA-Targeted Therapies and Emerging Agents Transform Treatment Landscape for Relapsed/Refractory Multiple Myeloma

Bispecific Antibodies Teclistamab and Talquetamab Show Promise in Multiple Myeloma Treatment

Sanofi's Rilzabrutinib Achieves Primary Endpoint in Phase 3 ITP Trial

Pfizer to Showcase Breakthrough Cancer Therapies at ASCO 2025 with Over 60 Presentations

LAG-3 Inhibitors Show Promise in Cancer Immunotherapy, Market Expected to Surge

Page 1 of 1225